DUBLIN – Aprea Therapeutics AB took in SEK512 million (US$56.4 million) in a series C round to continue development of its first-in-class cancer drug, APR-246, which is currently undergoing clinical trials in a swathe of cancer indications, all of which involve mutations in the p53 tumor suppressor.